IRLAB announced today that IRLAB's candidate drug mesdopetam (IRL790) is featured on the cover of the
"We are proud that IRLAB by means of our systems biology discovery strategy, ISP, has discovered and developed a candidate drug that is now featured on the cover of the prestigious scientific journal JPET", said
JPET,
In an earlier press release, it was announced that the paper was published online as part of JPET Fast Forward, which contains papers in manuscript form that have been accepted and published in JPET.
Publication: Waters, S. et al. Preclinical pharmacology of [2-(3-fluoro-5-methanesulfonylphenoxy)ethyl](propyl)amine (IRL790), a novel dopamine transmission modulator for the treatment of motor and psychiatric complications in Parkinson's disease.
For more information
Phone: +46 730 75 77 01
E-mail: nicholas.waters@irlab.se
About IRLAB
IRLAB is a Swedish research and development company that focuses on developing novel treatments in Parkinson's disease. The company's most advanced candidates, mesdopetam (IRL790) and IRL752, both of which completed Phase IIa-studies, intends to treat some of the most difficult symptoms related to Parkinson's disease: involuntary movements (PD-LIDs), psychosis (PD-P) and symptoms linked to cognitive decline such as impaired balance and increased risk of falls (PD-Falls). Through the proprietary research platform, ISP (The Integrative Screening Process), IRLAB discovers and develops drug candidates for central nervous system (CNS) related disorders where large and growing medical need exist. In addition to the clinical candidates, the ISP platform has also generated several CNS programs that are now in preclinical phase. IRLAB's Certified Adviser on Nasdaq First North Premier Growth Market is
https://news.cision.com/irlab-therapeutics-ab/r/irlab-s-mesdopetam-featured-on-cover-of-top-tier-publication-jpet,c3140632
https://mb.cision.com/Main/15440/3140632/1268853.pdf
(c) 2020 Cision. All rights reserved., source